Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
0.08 Anybody want to comment on this failing stock?
http://www.sec.gov/Archives/edgar/data/1089029/000149315214002951/nt10-q.htm
Today you could sell @ 0.08 Grab it , it is a good deal, over what is coming. JMO
We certainly hope so.
yak
When people start realizing how close they are in the FDA process and to commercializations this stock will fly
This stock it's beginning to awaken to its massive potential
One of the reasons for the recent price decline in CGNH is that one of their consultants, Scott Shedden, from the Jag days, passed away very unexpectedly a couple of months ago. His wife, who has significant cash problems, sold over 450000 shares through BMA Securities in a very unprofessional manner. I think he owned about 500000 share.
I hope the issued stock is restricted from trading for a year or two.... Then we only have to worry about this being a death spiral deal with a group that is out of reach of the SEC..
IMHO
yak
I think this has been brought down here to get loaded for a run back to $1 .
Would be nice to hear something from the company.
yak
$CGNH I filled some .135 today
$CGNH .20 let's go :)
$CGNH .155 and .17 on ask thin to .41
Ante, On agoracom.com states CGNH is still enrolling patients in their study according to "sources" at the Wayne State hospital sites.
Yak, I am well in the black again. News would be great.
Based on the past weeks activity (rise in PPS), we might be in for some good news... ???
IMHO
yak
Ante's thoughts on the video from Agoracom.
Thanks for providing link to this Cardiogenics' WDM Capital presentation; slides 16 & 17 provide important information:
Slide 16 -
1.Confirmation that 200 patient Beta Site Study to be completed in Q4 2013
2.Informs FDA Pivotal Study will require only 200 additional patients
3.Informs/confirms that FDA Pivotal Study will be conducted at Wayne State hospitals
Slide 17 -
1.FDA 200 patient Pivotal Study targeted completion date of Mid-Q1 (February?)
2.510K submission to FDA targeted late Q3 2014 (August?)
3.Partnering discussions to complete end of Q1 2014 (Partner announcement April ?)
4.Q4 2014 Launch target date in United States
Ante
Yak, I would like to take the credit but I nicked it from Agoracom.
nice link...thanks shark :)
I agree, no reason to slam this down.
It should recover.
yak
No reason for a slam down but if it happens again I will try and buy another 20k shares. Check out this video.
http://www.wdmcapital.com/uploads/lsc_slajdy/CardioGenics_IR_Warsaw.pdf
somebody slammed this down hard in the last 8 minutes..
farkers
yak
CGNH closed on a high last 2 days, although it was on the last trade of the day.
Makes me go Hmmmmmmmmmmmmmmm
but I like it.
yak
The Beta-site testing at Wayne State U hospitals has begun. I am surprised the PPS has flatlined.
Beta-Site Testing of the Company's QL Care(TM) Analyzer and Troponin-I Test Begins in Two Hospitals
MISSISSAUGA, Ontario, Aug. 21, 2013 (GLOBE NEWSWIRE) -- CardioGenics Holdings Inc. (CGNH), developer of the QL Care(TM) analyzer, an ultra-sensitive immunoassay point-of-care analyzer, and other products targeting the In-Vitro-Diagnostics testing market, announced today that it has commenced beta-site testing of its QL Care(TM) Analyzer and first cardiovascular test, Troponin-I. The beta-site testing was commenced in two hospitals affiliated with Wayne State University.
In accordance with the approved testing protocol, blood samples from approximately 200 patients presenting with chest pain will be analyzed for Troponin I by both the QL Care(TM) Analyzer and the Siemens ADVIA Centaur XP, a central laboratory-based immunoassay analyzer. The test results of the analyzed samples will be compared in order to document the "equivalence" of both devices. The Company expects beta-site testing to be completed within 10-12 weeks.
The results of this pilot testing will form the basis of the Company's 510(K) application to the FDA, as well as its corresponding application in the European Union for commercialization of the QL Care(TM) Analyzer and Troponin-I test. The Company currently anticipates final clinical testing to commence during Q4 of 2013.
"We look forward to obtaining our beta-site testing results so we can demonstrate that our QL Care(TM) Analyzer can deliver Troponin-I results within 15 minutes at the point-of-care, with the test sensitivity that, to date, has only been possible by using lab-based analyzers that take significantly longer than 15 minutes to provide results," said Dr. Yahia Gawad, CEO of CardioGenics. "With its ultra-sensitivity, and fast and accurate test results, the QL Care(TM) Analyzer is well positioned to remove the current limitations of point-of-care immunoassay testing, thereby improving patient outcomes and reducing the costs associated with such healthcare," continued Dr. Gawad.
Troponins are considered the "gold-standard" cardiac biomarkers for the diagnosis and management of myocardial infarctions (heart attack). The average time to deliver Troponin results across the U.S. is currently estimated to be 2.8 hours, which falls far short of the American Heart Association's guidelines for obtaining Troponin test results within sixty minutes (the so-called "Golden Hour"). CardioGenics intends to change this dynamic by not only providing lab-quality Troponin test results within 15 minutes but also by providing such results directly to the point-of-care at a significantly reduced cost, resulting in quicker and more effective treatment of patients presenting with chest pain and, ultimately, saving lives and significantly reducing related healthcare costs.
Yak, I bought back my trading stock today. With my core position I am at a new high for share ownership.
Good news today!
http://finance.yahoo.com/news/cardiogenics-announces-schedule-beta-testing-130000785.html
Finally something to chew on....
I was starting to wonder if CGNH had fallen off the edge of the earth.
yak
Approval clears the way for commencement of beta-site testing of the QL Care™
Analyzer in hospitals
MISSISSAUGA, Ontario – June 05, 2013 - CardioGenics Holdings Inc. (OTCBB: CGNH),
developer of the ultra-sensitive QL Care™ analyzer, an immunoassay Point-Of-Care
Analyzer, and other products targeting the In-Vitro-Diagnostics testing market,
announced today that it has received approval of its clinical testing protocol
from the Institutional Review Board of Wayne State University ("IRB"), which
approval now enables the Company to commence beta-site testing of its QL Care™
Analyzer and first cardiovascular test, Troponin-I.
The beta-site testing will initially take place in hospitals affiliated with
Wayne State University in Michigan. The Company is currently working with the
university to schedule the commencement of beta-site testing. In accordance with
the approved clinical testing protocol, the trial is targeting to enroll
approximately 200 patients whose blood samples will be analyzed by the QL Care™
Analyzer and its disposable self-metering test cartridge.
The purpose of the beta-site testing program is to test the QL Care™ Analyzer
and its first cardiovascular test, Troponin-I, in a real world hospital setting
in order to (a) document the performance of the QL Care™ Analyzer and the
Company's Troponin-I test in such setting and (b) establish that its performance
is equivalent to that of the Siemens ADVIA Centaur XP lab-based immunoassay
analyzer (the "Siemens Centaur XP").
Once beta-site testing is complete and the results have been analyzed, the
Company will make any final adjustments that may be necessary and then conduct
the final clinical testing, also in a hospital setting, the results of which
will form the basis of the Company's 510K application to the FDA, as well as its
corresponding application in the European Union for commercializing the QL Care™
Analyzer and Troponin-I test. The Siemens Centaur XP will also be the predicate
device against which the Company will compare the performance of its QL Care™
Analyzer and Troponin-I test in these final clinical tests.
"We are very excited to have received approval of the IRB of Wayne State
University to commence beta-site testing of our QL Care™ Analyzer and Troponin-I
test in its affiliated hospitals," said Dr. Yahia Gawad, CEO of CardioGenics.
"We look forward to documenting that our ultra-sensitive QL Care™ Analyzer can
deliver at the point-of-care, and in a 15-minute time frame, the test
sensitivity that, to date, has only been possible by using lab-based analyzers,"
continued Dr. Gawad.
ABOUT CARDIOGENICS HOLDINGS INC.
Through its operating subsidiaries, the Company develops ultra-sensitive
analyzers and other products targeting the immunoassay segment of the
Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a
proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a
number of diagnostic tests under development, the first of which will be a
series of cardiovascular diagnostic tests. As part of its core proprietary
technology, the Company has also developed a proprietary method for silver
coating paramagnetic microspheres (a fundamental platform component of
immunoassay equipment), which improve instrument sensitivity to light. The
Company's proprietary microspheres technology and SAVAsphere™ magnetic beads are
developed and marketed through the Company's Luxspheres subsidiary. The
Company's principal offices are located in Mississauga, Ontario, Canada. For
more information please visit www.cardiogenics.com and www.luxspheres.com.
Safe Harbor Statement - Certain statements made herein that are not historical
are forward-looking within the meaning of the Private Securities Litigation
Reform Act of 1995 and may contain forward-looking statements, with words such
as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan,"
"projected," "intend," and similar expressions to identify forward-looking
statements. These statements are based on the Company's beliefs and the
assumptions it made using information currently available to it. Because these
statements reflect the Company's current views concerning future events, these
statements involve risks, uncertainties and assumptions. The actual results
could differ materially from the results discussed in the forward-looking
statements. In any event, undue reliance should not be placed on any
forward-looking statements, which apply only as of the date of this press
release. Accordingly, reference should be made to the Company's periodic filings
with
the Securities and Exchange Commission.
SOURCE CardioGenics Holdings Inc.
A move into the 40s would be good news
The Market Monkeys giveth, and the market monkeys taketh away...
http://quotes.freerealtime.com/dl/frt/M?SA=quotes|Chart&IM=quotes&qm_page=93771&symbol=CGNH
yak
ahhhh Sedona & Dendron...2 great examples of WalledStreet© gone mad.
Prolly spearheaded my Milken.
Their all farking crooks.
If CGNH can pull one out of the bag, I too expect some exciting times for us lowly shareholders. We frickin deserve it !!!
yak
I also invested in SDNA and am aware of the "naked shorting" used to destroy that company.
If CGNH succeeds we could see a DNDN type rise if there is a forced cover of all the "grandfathered" shorts. The run up must last long to supercede the "market maker" exception but it can happen just like DNDN.
I am part of the group who has been fighting Naked Short selling since 2001. And I started following Jag, back when the CEO was also fighting NSS. I'm well versed in the battle that has robbed investors for well over 20 years now.
Anyway...
I'm happy to see some steady upward movement on CGNH, without it being hammered back down at every tick. Which is what we tend to see on most other penny stocks.
I am of the belief that CGNH has gone silent for some sort of contractual reason, and this rise in pps could spell the end of that quiet period.
Good luck to us all.
yak
CGNH is up again today.
Your point about the markets being unfair for a small investor is well taken. Hopefully you will recover enough funds on CGNH to make it worthwhile. I have some stock left which I purchased after the reverse split. Up to that point in time I had only traded Jag Media. My major penny stock losses occurred in other stocks.
BPTH is hopefully the real deal. If the FDA approves their drug I expect a significant price per share jump like in DNDN.
Good luck.
SJS: thanks for the tip, but I'm done with stocks until congress kicks some AZZ at the SEC and Finra, and cleans up the market.
Small players DO NOT have a chance the way things are run these days. As for CGNH, I got slaughtered with the last R/S..
my average is so high, CGNH would actually have to find a cure for heart attacks, for me to see a profit.
I can only hope to limit my losses during a run up.
yak
Yak, I have not sold yet as the stock continues to perform nicely.
If the volume picks up I smell something good. It would be nice to be right on one these pennies. Any positive news sends this issue much higher IMO.
I do suggest you take a look (as Ante initially suggested) at BPTH. I have done substantial research and if their antisense drug works it could be game changer. I actually had my own independent expert look at this company's explanation of their technology. The majority shareholder of the company is the premier cancer in the world, MD Anderson Cancer Center at U of Texas in Houston.
They are near the end of Phase I testing and there is no sign toxicity. If Phase II shows anti-leukemic properties (as in their animal studies and in Phase I as alluded to by the company) things will happen quickly for BPTH do to the paucity of any side effects.
In meantime, let us hope CGNH gets their act together.
Sorry, I know nothing about BPTH.... I don't follow or buy penny stocks anymore. I only keep track of the ones I still own and that have not been destroyed.
yak
SJS: the company has been very quiet for over a year. They are still fully reporting, and I'm not aware of any dilution in the shares. I've been watching the slow rise in the PPS as well.
I suspect someone is quietly accumulating. We are way over due for updates on both the spheres and the analyzer. And even though certain links show no discernible short position, don't forget this was once Jag Media, and I suspect a ton of shorts are parked in a desk somewheres.
http://ca.finance.yahoo.com/q/ks?s=CGNH
IMHO
yak
Yak, Any news on this stock?
Why the sudden stock price rise?
A stock originally mention by Ante on RB now has my full focus...BPTH.
I am thinking of selling my CGNH shares to buy more BPTH. Any thoughts?
Is there any explanation for the price per share increased today?
Off the timeline a bit but not this week dad. Watch and see for yourself. It will rocket in our opinion. Timelines can't always be accurate but this is the time in our opinion.
GEEZ! WRONG AGAIN!---
LOL!
MAYBE NEXT WEEK???
GL!
wholly carp...a post!!.. we can only hope that the trials go well..
Friday may have been a small hint that something is about to turn up the heat in our opinion. Something has to be getting ready from rumblings we have heard.
almost a full year for a new post...wow... hope you are right about news.
yak
Thats a long trend.... hope it breaks out soon..
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
359
|
Created
|
06/09/04
|
Type
|
Free
|
Moderators |
CardioGenics Holdings Inc. is engaged in business of development of products targeting the immunoassay segment of the point-of-care in vitro diagnostic (IVD) testing market. The Company is engaged in development of technology and products, which include The QL Care Analyzer (QLCA), Cardiovascular Tests and Paramagnetic beads. The QLCA is a point-of-care (POC) immunoassay analyzer. The QLCA uses a self-metering cartridge to perform immunoassay tests at the POC. To support the use of the QLCA, the Company develops approximately four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. Its immunoassay tests include Troponin I (TnI), Plasminogen Activator Inhibitor Type-1 (PAI-1), Heart Failure Risk Stratification (HFRS) and Heart Failure Genomics Risk (HFGR). The Company's TnI test product is in the pilot testing phase. Paramagnetic (magnetic) beads are the solid phase employed during immunoassays tests
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |